PET imaging of inflammation in atherosclerosis

Jason M. Tarkin,Francis R. Joshi,James H. F. Rudd
DOI: https://doi.org/10.1038/nrcardio.2014.80
IF: 49.421
2014-06-10
Nature Reviews Cardiology
Abstract:Key Points18F-fluorodeoxyglucose (FDG) PET imaging of atherosclerosis is a reliable and reproducible measure of vascular inflammation, which can be used as a surrogate end point in clinical drug trialsThe 18F-FDG PET signal indicates increased metabolic activity of macrophages, and probably also reflects contributions from local hypoxia and efficiency of tracer delivery by the microcirculationInitial data suggest that 18F-FDG PET provides prognostic information above clinical and anatomical assessment alone; however, the outcome of large, prospective studies is awaitedSeveral tracers with established roles in cancer imaging (68Ga-DOTATATE, 11C-PK11195, and 18F-fluoromethylcholine) might be more-specific for vascular inflammation and better-suited to coronary artery imaging than 18F-FDG
cardiac & cardiovascular systems
What problem does this paper attempt to address?